GSK's Blenrep Makes Strong Comeback with UK Approval of First Myeloma Combination Therapy

After experiencing2022After the global market withdrawal in year,GSKAntibody-Drug ConjugatesBlenrepFinally, a new dawn has arrived. Recently, the UK Medicines and Healthcare products Regulatory Agency (MHRA) was the first to approveBlenrepAs part of two different combination therapies, used to treat patients with multiple myeloma who have previously received at least one prior therapy.

This approval allowsBlenrepWith TakedaVelcade(Bortezomib) or Bristol-Myers Squibb'sPomalyst(Pomalidomide) in combination with dexamethasone, for second-line treatment of multiple myeloma. Also,GSKPromote BlenrepTowards Annual Sales Exceeding30Billion pounds (approximately40USD billion) plan. DespiteGSKThere is uncertainty in the core vaccine business, butBlenrepPotential global re-listing gives the company confidence to2031The sales target for the year has been raised to exceed400Billion pounds.

 Clinical Trial Data Shines

Despite the fact that previouslyBlenrepAs a single-agent therapy in third-line multiple myeloma treatment3It encountered setbacks in the phase trial, leading to its withdrawal, but in the combination therapy trial, it demonstrated strong potential.

InDREAMM-7In the trial,BlenrepIn collaboration withVelcadeAnd dexamethasone (Vd) in combination therapy defeated Johnson & Johnson'sDarzalex。Blenrep-VdReduced the risk of disease progression or death59%, andDarzalex-VdIn comparison,GSKThe treatment regimen also helped patients prolong their survival period and reduce the risk of death.42%。

InDREAMM-8In the trial,BlenrepAndPomalystAnd dexamethasone (Pd) has also achieved significant results, in combination withVelcade-PdIn comparison, the risk of disease progression or death was reduced.48%。

 Global Market Outlook and Competition

Currently, except for the UK,BlenrepThe combination therapy is also in the world14The region is under review. In the United States,FDAIt is expected to be this year7Month23Make an approval decision before the day.

In the global market,BlenrepWill collaborate with Johnson & Johnson and Legend BiotechCAR-TTherapyCarvyktiUnfold competition. However, due to supply issues, Johnson & Johnson...2023Year suspendedCarvyktiPromotion in the UK.BlenrepAs an off-the-shelf therapy, compared to those that require the use of the patient's ownTCells, Complex Production ProcessesCAR-T Therapy, with the advantage of convenience.

BlenrepThe return of not only forGSKIt brings new hope and more treatment options for patients with multiple myeloma. With the gradual opening of the global market,BlenrepIs expected to play an important role in the future field of cancer treatment.

Information Reference:fierce biotech

●Another Chinese medicine company is on the verge of delisting, with a market value of less than 5 billion...

●Three Rounds of Layoffs in a Year! This Pharmaceutical Company "Slims Down" Again

●Nearly 300 Layoffs! Restructuring Plan of Roche Subsidiary Comes to Light